SS Innovations International Inc.
SSII evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SSII—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SSII
SS Innovations International Inc. (SSII) is an early-stage revenue company in the healthcare industry that has relied on debt and equity financing to fund operations, with net losses of $12.13 million in 2025 and $19.15 million in 2024 [sec].
Key risk: Continued operating losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for SS Innovations International Inc..
SS Innovations International Inc. (SSII) is an early-stage revenue company in the healthcare industry that has relied on debt and equity financing to fund operations, with net losses of $12.13 million in 2025 and $19.15 million in 2024 [sec].
- Cash and equivalents of $22.7M as of 2026-06-30 [sec].
- Total revenue of $13.9M for the period ended 2026-06-30 [sec].
- Net loss of $2.7M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $38.2M as of 2026-06-30 [sec].
- Net losses of $12.13 million in 2025 and $19.15 million in 2024 [sec].
What works
- The company has generated revenue of $13.9M as of 2026-06-30, indicating some commercial traction [sec].
- Shareholders' equity of $38.2M as of 2026-06-30 provides a capital base for operations [sec].
What to weigh
- The company has incurred net losses since inception, with a net loss of $2.7M for the period ended 2026-06-30 and $12.13M in 2025 [sec].
- The company plans to raise additional capital through private or public offerings, and if unable to do so, may face limitations on expansion, R&D, and marketing [sec_mda · as of 2026-05-13].
- As an early-stage revenue company in a highly competitive industry, the company faces risks, uncertainties, and expenses that make it difficult to evaluate performance and forecast future results [sec · filed 2026-05-01].
From the filings
Quoted directly from source documents.
Net losses in recent years
“For the years ended December 31, 2025 and December 31, 2024, we had net losses of $12.13 million and $19.15 milli”
SEC filings · May 1, 2026
Dependence on future capital raises
“During the balance of the year ending December 31, 2026, the Company plans to raise additional capital through further private or public offerings of its securities. However, if we are unable to do so and if we experience a shortfall in operating capital, we could be faced with having to limit our expansion plans, research and development efforts and marketing activities.”
SEC MD&A · May 13, 2026
Early-stage company risks
“Our prospects must be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by an early-stage revenue company in a highly competitive healthcare industry.”
SEC filings · May 1, 2026
Risks & what to watch (3)›
Key risks
- Continued operating losses — The company has incurred net losses since inception, with $2.7M loss in H1 2026 and $12.13M in 2025 [sec].
- Need for additional financing — Company plans to raise capital; failure may limit expansion, R&D, and marketing [sec_mda · as of 2026-05-13].
- Early-stage competitive risks — As an early-stage revenue company in a competitive industry, performance and forecasting are difficult [sec · filed 2026-05-01].
What to watch
- Ability to raise additional capital through private or public offerings [sec_mda · as of 2026-05-13].
- Progress in product development, clinical and regulatory timelines [sec · filed 2026-08-13].
- Trend in net losses and cash burn rate [sec].
Sources: News · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run SS Innovations International Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SS Innovations International Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
26.4 months
D/E 0.82 · 5% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$650K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 36,276 | $181K |
| alti global, inc. | 20,555 | $103K |
| ifc & insurance marketing, inc. | 16,730 | $84K |
| state street corp | 15,586 | $78K |
| pnc financial services group, inc. | 13,627 | $68K |
| goldman sachs group inc | 10,601 | $53K |
| millennium management llc | 10,226 | $51K |
| morgan stanley | 3,000 | $15K |
| nfsg corp | 1,316 | $7K |
| steward partners investment advisory, llc | 1,100 | $6K |
Showing top 10 of 16 institutional holders of SS Innovations International Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 11, 2026- % of float
- 0.1%
- Days to cover
- 1.5
- Shares short
- 74,555
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SSII short interestFrequently asked questions
What is the AI investment thesis for SS Innovations International Inc.?
SS Innovations International Inc. (SSII) is an early-stage revenue company in the healthcare industry that has relied on debt and equity financing to fund operations, with net losses of $12.13 million in 2025 and $19.15 million in 2024 [sec].
Who is the CEO of SS Innovations International Inc.?
Dr. Sudhir Prem Srivastava M.D. is the chief executive officer of SS Innovations International Inc. (SSII).
Where is SS Innovations International Inc. headquartered?
SS Innovations International Inc. (SSII) is headquartered in Gurugram, India.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.